This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watson, D C Articles by Szu, S C Search for Related Content PubMed PubMed Citation Articles by Watson, D C Articles by Szu, S C

 Previous Article  |  Next Article 

Infect Immun. 1992 November; 60(11): 4679-4686

Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine.

Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, Bethesda, Maryland 20892.

ABSTRACT

Serious infections with salmonellae remain a threat in many human populations. Despite extensive study of salmonella infections in animals and clinical experience with killed cellular vaccines, there are no vaccines against serotypes other than Salmonella typhi licensed for human use. Serum antibodies to the O-specific polysaccharide (O-SP) of salmonellae protect mice against invasive infection. In order to render it immunogenic, we have conjugated the O-SP of Salmonella typhimurium to carrier proteins by various schemes. O-SP conjugated to tetanus toxoid (O-SP-TT) elicited antibodies in outbred mice after three subcutaneous injections without adjuvant. The O-SP alone elicited no detectable antibody. The antibody response to O-SP-TT was boosted by successive doses and consisted of immunoglobulin G (IgG) and IgM. Most mice only produced antibodies specific for the abequose (O:4 factor) region of the O-SP. Occasional animals also produced antibodies to the core oligosaccharide. Immunized mice were protected against intraperitoneal challenge with S. typhimurium, demonstrating a 160-fold increase in the 50% lethal dose. Passive immunization with conjugate-induced IgM or IgG also protected against challenge. These results indicate that an O-SP-TT conjugate, when given by a route and formulation acceptable for human use, protects mice against challenge with S. typhimurium.

This article has been cited by other articles:

• Kashef, N., Behzadian-Nejad, Q., Najar-Peerayeh, S., Mousavi-Hosseini, K., Moazzeni, M., Djavid, G. E. (2006). Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate.. J Med Microbiol 55: 1441-1446 [Abstract] [Full Text]  
• Mastroeni,, P., Menager, N. (2003). Development of acquired immunity to Salmonella. J Med Microbiol 52: 453-459 [Abstract] [Full Text]  
• Konadu, E. Y., Lin, F.-Y. C., Ho, V. A., Thuy, N. T. T., Van Bay, P., Thanh, T. C., Khiem, H. B., Trach, D. D., Karpas, A. B., Li, J., Bryla, D. A., Robbins, J. B., Szu, S. C. (2000). Phase 1 and Phase 2 Studies of Salmonella enterica Serovar Paratyphi A O-Specific Polysaccharide-Tetanus Toxoid Conjugates in Adults, Teenagers, and 2- to 4-Year-Old Children in Vietnam. Infect. Immun. 68: 1529-1534 [Abstract] [Full Text]  
• Flanagan, M.P., Battisti, G., Michael, J.G. (1996). Oral administration of Escherichia coli in enteric coated microparticles induces serum antibodies against lipopolysaccharide antigens. Innate Immunity 3: 481-489 [Abstract]